Contract-Resource-Outsourcing-IndustryNews

81. ThromboGenics And BioInvent Start Phase II Trial Of TB-402, A Novel, Long Acting Anticoagulant For Deep Vein Thrombosis (DVT) Prophylaxis 2/25/2009
    ThromboGenics NV and co-development partner BioInvent International announce recently that the first patient has been enrolled in the Phase II trial with their longacting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery.
82. Basilea Pharmaceutica Files Claims Against Johnson&Johnson Over Its Handling Of Ceftobiprole (ZEFTERA/Zevtera) Clinical Studies 2/24/2009
    Basilea Pharmaceutica Ltd. announces that it has filed claims in arbitration against Johnson&Johnson, and affiliated companies related to delays in approval of ceftobiprole.
83. Moving Clinical Trials Overseas Tests The System's Safety, Efficacy 2/19/2009

    Major U.S. drug companies are increasingly performing clinical trials in developing countries, raising serious concerns about the efficacy, ethics and economics of drug development, according to a study in the current issue of the New England Journal of Medicine.

84. Teva And Active Biotech Announce Fast Track Status For Multiple Sclerosis Drug 2/17/2009
    Teva Pharmaceutical Industries, a generic pharmaceutical company, and Sweden-based pharmaceutical company Active Biotech have announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis, has received a fast track designation from the FDA.
85. SCORR Marketing Named Agency Of Record By DaVita Clinical Research 2/11/2009
    SCORR Marketing, a strategic marketing agency, has been hired by DaVita Clinical Research as their agency of record. SCORR will provide DaVita Clinical Research with a strategic marketing plan, brand development and a Web community for patients, investigators and pharmaceutical development companies.
86. Pfizer - Wyeth: Good Deal - Bad Deal? 1/26/2009
    If Pfizer and Wyeth merge to create a $60B company, will it be a good deal or a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially a bad deal for both companies.
87. ICON Recognised As Research Company Of The Year At The PharmaTimes Awards 1/22/2009
    ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, recently announced that it has been named "Research Company of the year" at the annual PharmaTimes awards.
88. Merrion Announces License Agreement With Novo Nordisk To Develop Oral Formulation Of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment In Merrion 1/22/2009
    Merrion Pharmaceuticals and Novo Nordisk A/S, a world leader in diabetes, have entered into a Development and License Agreement to develop and commercialise oral formulations of a Novo Nordisk proprietary GLP-1 receptor agonist, using Merrion's proprietary GIPET® technology.
89. AvivoClin's Expansion Continues With The Addition Of Microdosing And Central Lab Services 1/21/2009
    Azopharma Product Development Group, Inc.™ ("Azopharma") is excited to announce the addition of Microdosing and Central Lab services to its clinical pharmacology research facility, AvivoClin Clinical Services™, located in Daytona Beach, Florida.
90. New Treatment Option For The Estimated 6 Million Americans Living With This Chronic, Debilitating Condition 1/20/2009
    Forest Laboratories, Inc. and Cypress Bioscience, Inc. recently announced that Savella™ (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.